Posterior reversible encephalopathy: manifestations, diagnosis, treatment (clinical case)

Objective. To analyse the clinical features of posterior reversible encephalopathy syndrome. Design and methods. We carried out analysis and systematisation of national and international literature on the pathogenesis, clinical manifestations and treatment of posterior reversible encephalopathy. Results. The main risk factors, etiology and differential diagnosis of this syndrome are considered. A clinical case of posterior reversible encephalopathy manifested in a patient with hypertension is presented. Conclusions. Due to its rare occurrence, the information on the pathogenesis, clinical manifestations, differential diagnosis and treatment of posterior reversible encephalopathy remains scarce. Advancements in diagnostic methods, in particular magnetic resonance imaging, contribute to better detection and differentiation of this disease. Spontaneous regression of clinical manifestations of the disease is often observed, but irreversible cases can occur.

1. Barba L, Carrubba C, Spindler K, Weise CM, Sachs T, Foschi M, et al. Posterior reversible encephalopathy syndrome associated with antibiotic therapy: a case report and systematic review. Neurol Sci. 2024;45(9):4151–4159. https://doi.org/10.1007/s10072-024-07545-1

2. Ando Y, Ono Y, Sano A, Fujita N, Ono S. Posterior reversible encephalopathy syndrome: a review of the literature. Internal Medicine. 2022;61(2):135–141. https://doi.org/10.2169/internal-medicine.7520-21

3. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. Journal of Neurology. 2017;264(8):1608–1616. https://doi.org/10.1007/s00415-016-8377-8

4. Bhangu JK, Javed K, Manshahia PK, Nahar S, Kanda S, Chatha U, et al. The association of hypertension with posterior reversible encephalopathy syndrome in systemic lupus erythematosus patients: a systematic review. Cureus. 2023;15(12): e50620. https://doi.org/10.7759/cureus.50620

5. Gao B, Lyu C, Lerner A, McKinney AM. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry. 2018;89(1):14–20. https://doi.org/10.1136/jnnp-2017-316225

6. Racchiusa S, Mormina E, Ax A, Musumeci O, Longo M, Granata F. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature. Neurol Sci. 2019:40(5):915–922. https://doi.org/10.1007/s10072-018-3651-4

7. Largeau B, Boels D, Victorri-Vigneau C, Cohen C, Salmon Gandonnière C, Ehrmann S. Posterior reversible encephalopathy syndrome in clinical toxicology: a systematic review of published case reports. Front Neurol. 2020;10:1420. https://doi.org/10.3389/fneur.2019.01420

8. Surzhikova EV, Morozova TG. Posterior reversible encephalopathy syndrome. Smolensk Medical Almanac. 2021;3:108-110. (In Russ.)

9. Srichawla BS, Fang T, Kipkorir V, Garcia-Dominguez MA. Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review. Annals of Medicine and Surgery. 2024;86(3):1251–1260. https://doi.org/10.1097/MS9.0000000000001407

10. Pereira PR, Pinho J, Rodrigues M, Rocha J, Sousa F, Amorim J, et al. Clinical, imagiological and etiological spectrum of posterior reversible encephalopathy syndrome. Arq Neuro-Psiquiatr. 2015;73(1):36–40. https://doi.org/10.1590/0004-282X20140176

11. Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One. 2012;7(9): e44534. https://doi.org/10.1371/journal.pone.0044534

12. Orlando C, Milani GP, Simonetti GD, Goeggel Simonetti B, Lava SAG, Wyttenbach R, et al. Posterior reversible leukoencephalopathy syndrome associated with acute postinfectious glomerulonephritis: systematic review. Pediatr Nephrol. 2022;37(4):833–841. https://doi.org/10.1007/s00467-021-05244-z

13. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6(4):253–258. https://doi.org/10.1007/s11523-011-0201-x

14. Kornilov BN, Chugunova SA, Popov MM, Fedorov NN. Clinical case of posterior reversible encephalopathy syndrome in a young female patient. Practical Medicine. 2021;19(5):82–86. (In Russ.)

15. Pandita A, Lehmann DF. Magnesium sulfate treatment correlates with improved neurological function in posterior reversible encephalopathy syndrome (PRES): report of a case. Neurologist. 2018;23(2):65–66. https://doi.org/10.1097/NRL.0000000000000174